Our study in patients overexpressing the HER2 gene (HER2-positive) shows that FGFR1 gene amplification is associated with a poor tumor response to both anti-HER2 treatments, trastuzumab and trastuzumab plus pertuzumab. The gene discussed is FGFR1; the disease is neoplasm.